Northwest Sued Over Cancer Vaccine Claim

Law360, New York (August 29, 2007, 12:00 AM EDT) -- Northwest Biotherapeutics, which saw its share price more than double after the biotechnology company announced approval of the world’s first brain cancer vaccine, faces two purported securities class actions for allegedly deceiving investors with misleading statements.

Investors filed two separate actions in the U.S. District Court for the Western District of Washington this month, alleging that the Bothell, Wash.-based company issued inaccurate statements when it revealed in July that it received the green light in Switzerland to market its DCVax(R)-Brain drug treatment.

Investors claimed in the...
To view the full article, register now.